Aligos Therapeutics (ALGS) Company Statistics | The Fly

Search...

/

Dashboard

Charting

KPIs

Stock Screener

ETF Screener

Earnings Calendar

Events Calendar

Syndicate

Street Research

Portfolios

Alert Settings

Aligos Therapeutics (ALGS) Company Statistics | The Fly

© 2026 The Fly Inc.

The Fly Cast

Press play to listen

©

Aligos Therapeutics

· ALGS

Dashboard

Financials

Ratios

Valuation

Statistics

35.094 M

+0.18%

General

Market Cap: $35.09M
Enterprise Value: $7.96M
Shares Outstanding: 6,190,000
Dividend: —
Employees: —
Revenue Per Employee: —

Fundamental Ratios (TTM)

Gross Margin: 99.18%
Operating Margin: -250.63%
Net Profit Margin: -241.01%
FCF Margin: -299.90%
ROA: -114.53%
ROE: -160.72%
ROIC: -191.73%
Current Ratio: 2.19
Debt-to-Equity: 0.11
Revenue Per Employee: —

Valuation (TTM)

P/E: —
PEG: —
P/S: 1.11
P/FCF: —
P/B: 1.09
EV/EBITDA: -0.11

Growth

Rev 1Y: -44.59%
Rev 1Y Fwd Est: 1546.41%
Rev 3Y (CAGR): -46.03%
Rev 5Y (CAGR): —
Rev 10Y (CAGR): —
EPS 1Y: —
EPS 1Y Fwd Est: —
EPS 3Y (CAGR): —
EPS 5Y (CAGR)

Income Statement (TTM)

Revenue: $31.52M
Gross Margin: 99.18%
Operating Expenses: $110.26M
Operating Income: -$78.99M
Net Profit: -$75.96M

Balance Sheet

—

EPS 10Y (CAGR)

—

Cash and Equivalents: $30.38M
Working Capital: $33.78M
Total Assets: $66.33M
Net Debt: -$26.88M
Total Liabilities: $34.44M
Total Equity: $31.88M

Cash Flow Statement (TTM)

Cash Flow from Operations: -$94.17M
Cash Flow from Investing: $105.59M
Cash Flow from Financing: $228K
Free Cash Flow: -$94.52M
Capital Expenditures: $355K